Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/11/2026

1. ORCL
2. ADBE
3. SPY
4. RH
5. CPRT
6. ACVA
7. SEDG
8. QQQ
9. TENB
10. SPCX

Go back to Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
(NASDAQ: PTGX) Delayed: 148.18 +3.02 (2.08%)
Previous Close $145.16    52 Week High $24.52 
Open $147.18    52 Week Low $10.02 
Day High $150.48    P/E N/A 
Day Low $145.82    EPS $0.00 
Volume 478,038